Clinical trials: Condition
Iron Overload Due to Repeated Red Blood Cell Transfusions
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload.
- Trial name
- TWICE (NCT03802916)
- Testing
- Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage)
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 30 people
- Sponsor
- ApoPharma
HIV/AIDS, HIV Infections
Enhancing Sexual Safety: Couples' Communication and HIV Testing Among YMSM
The purpose of this study is to compare different ways to deliver the couples HIV Testing and Counseling (CHTC) intervention that is suited for adolescents and young adults.
- Trial name
- WeTestATN156 (NCT04289116)
- Testing
- We Test, IHTC
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Florida State University
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in combination with DMARDs in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to DMARDs.
- Trial name
- NCT00996606
- Testing
- DMARDs, Tocilizumab
- Where
- 11 sites in Italy
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myeloid, Acute
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
This is an open label study to assess the suitability of CPX-351 as first intensive therapy in elderly (age ≥60 years) patients with AML. Patients may have received prior AML treatment with non-intensive regimens, e.g.
- Trial name
- NCT03335267
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Weill Medical College of Cornell University
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Breast Cancer
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
The main objective of the trial is to compare Invasive Disease-Free Survival (IDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy with 1 year of bevacizumab.
- Trial name
- NCT00528567
- Testing
- Bevacizumab, Standard adjuvant chemotherapy
- Where
- 403 sites in United States, Argentina and 38 more
- Volunteers
- 2,591 people
- Sponsor
- Hoffmann-La Roche
Stroke, Acute, Cerebral Infarction
Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
The Virtual Reality Glove for Hand and Arm Rehabilitation (vREHAB) trial is a randomized, controlled, phase 3 trial aiming to evaluate the safety, usability, and efficacy of a virtual reality biofeedback system (Neofect RAPAEL…
- Trial name
- vREHAB (NCT03741400)
- Testing
- Neofect RAPAEL Smart Glove
- Where
- 4 sites in United States, Belgium
- Volunteers
- 60 people
- Sponsor
- Stanford University
Bipolar Disorder, Depression
Depression, Obesity and Inflammatory Markers
The purpose of this study is to better understand the relationship between bipolar disorder, body weight, and inflammation in the body (N=180).
- Conditions
- Bipolar Disorder, Depression, Obesity
- Trial name
- NCT02765100
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Weill Medical College of Cornell University
Iron Deficiency Anemia
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
The primary objective of this study is to assess the safety of an investigational intravenous iron (ferric carboxymaltose [FCM]) or an equal dose of iron dextran and explore the mechanism of hypophosphatemia following…
- Trial name
- NCT01307007
- Testing
- Ferric Carboxymaltose (FCM), Iron Dextran Injection
- Volunteers
- 69 people
- Sponsor
- American Regent, Inc.
Acute Otitis Media
Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
The investigators will study whether, in young children with acute otitis media (AOM), shortening length of antibiotic treatment as a strategy for reducing antimicrobial resistance provides satisfactory clinical outcome.
- Trial name
- NCT01511107
- Testing
- Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days
- Where
- 2 sites in United States
- Volunteers
- 520 people
- Sponsor
- Alejandro Hoberman
Depression
Measuring Quality of Decisions About Treatment of Depression
The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of depression.
- Trial name
- NCT01152307
- Testing
- DVD/Booklet: Coping with Symptoms of Depression
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- University of Massachusetts, Boston
Macular Degeneration, Retinal Drusen
Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen.
- Trial name
- NCT02569892
- Testing
- Pascal Retinal Laser Photocoagulator
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Stanford University
Adjustment Disorder With Anxious Mood
PH94B in the Treatment of Adjustment Disorder With Anxiety
This placebo-controlled clinical study is designed to evaluate the efficacy, safety and tolerability of administration of PH94B nasal spray four times per day as a treatment of Adjustment Disorder with Anxiety symptoms in adults.
- Trial name
- NCT04404192
- Testing
- PH94B
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- VistaGen Therapeutics, Inc.
Type 2 Diabetes
Well-child Visit Video Project
The purpose of this study is to determine if incorporating videos on the importance of minimizing infant sugar-containing beverage (SCB) consumption into well-child visit protocols increases parents' SCB-related knowledge and…
- Trial name
- NCT05011292
- Testing
- Educational Video about SCB, Survey on child feeding and related knowledge and practices, Educational Video other than SCB
- Where
- United States
- Volunteers
- 388 people
- Sponsor
- Emory University
Triple Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast…
- Trial name
- NCT05112536
- Testing
- Trilaciclib, Cylophosphamide, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- G1 Therapeutics, Inc.
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Liver Cirrhosis, Biliary
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
Primary Biliary Cholangitis (PBC) is a serious, life-threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver…
- Trial name
- COBALT (NCT02308111)
- Testing
- Obeticholic Acid (OCA)
- Where
- 181 sites in United States, Argentina and 29 more
- Volunteers
- 334 people
- Sponsor
- Intercept Pharmaceuticals
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)
This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older.
- Trial name
- NCT01204671
- Testing
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 4,659 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Autism Spectrum Disorder
Effects of Lactobacillus Plantarum PS128 in Children With ASD
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms.
- Trial name
- NCT05307744
- Testing
- PS128
- Where
- Taiwan
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
This study used 3 different formulations of tetravalent CYD dengue vaccine. The primary objective of the study was to evaluate the neutralizing antibody response after 2 doses of two different formulations of tetravalent dengue…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Trial name
- NCT00617344
- Testing
- Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
- Where
- 5 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.